Cambrex’s small scale API expansion open in Iowa, US

By Flora Southey contact

- Last updated on GMT

Cambrex's Charles City, Iowa, US plant
Cambrex's Charles City, Iowa, US plant
Cambrex Corporation has completed the expansion of its small scale active pharmaceutical ingredient (API) capacity at its Charles City, Iowa, US-based plant.

The expansion has added two 500-gallon glass lined reactors and a third small scale work centre to the facility, which the firm told allows for greater flexibility.

“The new small scale work centre further increases our flexibility for customer projects, particularly at the key development stages,” ​said vice-president of sales and business development Simon Edwards.

Cambrex said the expansion will support new and existing customers. 

“By investing in our capabilities at either end of the manufacturing scale, we continue to offer new and existing customers a manufacturing continuum and are well positioned to handle customer projects throughout the entire small molecule lifecycle,” ​Edwards told us.

The firm did not disclose the expansion cost.

The news follows two recent announcements regarding Cambrex’s investment in high potency active pharmaceutical ingredients (HPAPIs).

In August this year, Cambrex confirmed​ plans it would start building a facility for HPAPIs at the Charles City site, which is due to open in 2019.

Last month​, Cambrex said would install development and analytical equipment for the manufacturer of HPAPIs at its Milan, Italy-based site.

Related news

Related product

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Related suppliers